✦ LIBER ✦

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

✍ Scribed by Dorte Nielsen; Per Dombernowsky; Susanne Kornum Larsen; Ole Paaske Hansen; Torben Skovsgaard

Publisher: Springer
Year: 2000
Tongue: English
Weight: 115 KB
Volume: 46
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800000178

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cisplatin, epirubicin, and lonidamine co

Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study

✍ L. Dogliotti; S. Danese; A. Berruti; P. Zola; T. Buniva; A. Bottini; G. Richiard 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 162 KB

Dose-finding study of weekly docetaxel,

Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer

✍ S. H. Waters; A. Gillibrand; H. Berry; S. Kumar; G. Velikova; D. J. Dodwell; Tim 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 223 KB

Cisplatin and escalating doses of paclit

Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study

✍ Mario Nardi; Salvatore De Marco; Alessandra Fabi; Alessandra Aloe; Elena Magnani 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 70 KB

A phase II study of intensive-dose epiru

A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer

✍ T. Langenbuch; K. Mross; W. Jonat; D. K. Hossfeld 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 450 KB

Paclitaxel, cisplatin, and epirubicin fi

Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in Stage III and IV ovarian carcinoma : Long term results of a Phase II study

✍ Christos A. Papadimitriou; Lia A. Moulopoulos; Georgios Vlahos; Zannis Voulgaris 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Background: The combination of paclitaxel with cisplatin or carboplatin has become the preferred chemotherapy regimen in the treatment of epithelial ovarian carcinoma. anthracyclines also have activity in this disease. we conducted a phase ii study by using the combination of paclitaxel, cisplat

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB